Low-cost Chinese APIs throng Indian market illegally, pose health risk to people


Low-cost Chinese active pharmaceutical ingredients (APIs) continue to throng the Indian market through illegal route, posing a health risk to the people. APIs such as erythromycin stearate, used to treat a wide variety of bacterial infections, are being imported by certain Indian drug companies /traders from China without requisite registration certificates and the material is being sold at a very low price in India.

A representation in this regard has already been made to Drugs Controller General of India (DCGI) and the matter is being investigated by regulatory authority.

Last month, it was brought to the notice of the DCGI that erythromycin stearate of Shanong Sinder Technology, China was being openly sold by Chennai-based drug companies/traders. It is understood that the importers had lacked certificate of product registration of erythromycin stearate in India thus casting suspicion on quality and efficacy of the product. The API was being supplied by the importers in the domestic market at a very cheap rate, nearly 25% less than the prevailing market rate.

Taking serious note of this, pharmaceutical industry has requested the DCGI to conduct inquiry into alleged malpractice committed by the importers and, if found guilty, strict action should be taken against the wrongdoers and all materials which have been sold as API or as finished formulation should be retrieved from the companies as the product originating from unregistered source might harm the health of the people.

The industry had demanded that samples from batches of pharmaceutical products being imported from ports should be checked by central drugs laboratory to rein in circulation of substandard unregistered products in the domestic market.

Earlier also, the pharmaceutical industry had raised concern over substandard quality Chinese APIs supplied by the importers. The industry had demanded setting up of an API Monitoring Cell which would help them get genuine APIs from importers as well as domestic manufacturers.


Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

Webinar on ‘OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH’

WhatsApp Group for Pharma Literati